Falcon Point Capital LLC lowered its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) by 3.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 855,101 shares of the company’s stock after selling 26,142 shares during the period. Falcon Point Capital LLC’s holdings in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share were worth $9,432,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the company. Trexquant Investment LP raised its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 30.7% in the second quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock valued at $336,000 after buying an additional 7,169 shares during the period. Sei Investments Co. raised its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after buying an additional 2,900 shares during the period. State of New Jersey Common Pension Fund D raised its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 27.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 42,090 shares of the company’s stock valued at $464,000 after buying an additional 9,175 shares during the period. Acadian Asset Management LLC raised its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 9.7% in the second quarter. Acadian Asset Management LLC now owns 1,672,207 shares of the company’s stock valued at $18,444,000 after buying an additional 147,907 shares during the period. Finally, US Bancorp DE bought a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the first quarter valued at about $121,000. 71.03% of the stock is currently owned by institutional investors.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ AVDL) opened at 8.62 on Friday. The company has a market capitalization of $345.52 million, a P/E ratio of 9.10 and a beta of 1.37. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 12 month low of $8.14 and a 12 month high of $15.45. The company’s 50 day moving average price is $10.09 and its 200 day moving average price is $9.97.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.14. The company had revenue of $46.30 million during the quarter, compared to analysts’ expectations of $45.17 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a return on equity of 29.86% and a net margin of 21.13%. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s revenue for the quarter was up 19.0% on a year-over-year basis. Analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post $0.54 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/falcon-point-capital-llc-has-9-43-million-stake-in-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-nasdaqavdl/1478582.html.

Several analysts have recently issued reports on the company. Roth Capital set a $15.00 target price on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research lowered Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $14.75.

In other Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share news, Director Craig R. Stapleton bought 31,013 shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share stock in a transaction that occurred on Monday, May 22nd. The stock was acquired at an average cost of $9.85 per share, for a total transaction of $305,478.05. Following the completion of the transaction, the director now directly owns 507,678 shares in the company, valued at $5,000,628.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of the business’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $10.68, for a total value of $2,787,480.00. The disclosure for this sale can be found here. 5.07% of the stock is owned by insiders.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Want to see what other hedge funds are holding AVDL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL).

Institutional Ownership by Quarter for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with Analyst Ratings Network's FREE daily email newsletter.